Physician profile
Steven Leibowitz
NPI 1679631014
$147,378.42
in general payments reported to CMS, 2019-2025
16 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,586 · 2020: $7,791 · 2021: $5,915 · 2022: $17K · 2023: $75K · 2024: $24K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $47K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $18K · Consulting Fee: $10K · Food and Beverage: $7,418 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $47,350.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,920.63 |
| Travel and Lodging | $18,279.73 |
| Consulting Fee | $10,025.00 |
| Food and Beverage | $7,417.50 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $110,315.74 | 2019-2023 | Tepezza |
| Amgen INC. | $36,030.99 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $215.69 | 2025 | |
| Bausch & Lomb Americas INC. | $168.05 | 2023-2025 | Xiidra, Miebo |
| Averitas Pharma INC. | $118.74 | 2025 | Qutenza |
| Galderma Laboratories, L.P. | $107.64 | 2019 | |
| Argenx US, INC. | $98.96 | 2025 | |
| Recordati_rare_diseases_inc. | $87.67 | 2025 | Isturisa |
| Sun Pharmaceutical Industries INC. | $70.62 | 2022-2023 | Cequa |
| Shire North American Group INC | $41.01 | 2019 | |
| Dompe US, INC. | $33.81 | 2021 | |
| Axogen | $19.84 | 2023 | Avance Nerve Graft |
| Novartis Pharmaceuticals Corporation | $18.41 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $17.95 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $17.44 | 2024 | Tyrvaya |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $15.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Leibowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.